Examkin

Soru

Zorluk: Çok zorPediatric Endocrine Disorders

A macrosomic male infant born at 3939 weeks gestation develops persistent hypoglycemia. At 2424 hours of life, despite receiving a continuous intravenous infusion of 10%10\% dextrose at a glucose infusion rate (GIR) of 88 mg/kg/min, his point-of-care blood glucose is 4040 mg/dL. He is lethargic but maintaining his airway and hemodynamic stability. The medical team suspects congenital hyperinsulinism and prepares to definitively evaluate and manage his condition.

Arrange the following steps in the optimal sequential order for the diagnostic workup and management of this patient.

  1. 1Draw a critical blood sample (insulin, C-peptide, ketones, free fatty acids) while the blood glucose remains <50< 50 mg/dL.
  2. 2Administer intravenous glucagon and measure the blood glucose response at 1515 to 3030 minutes.
  3. 3Titrate the intravenous glucose infusion rate (GIR) upward (e.g., 1212 to 1515 mg/kg/min) to achieve stable normoglycemia.
  4. 4Initiate a trial of oral diazoxide to chronically suppress endogenous pancreatic insulin secretion.
  5. 5Perform an 18F-DOPA PET scan and targeted genetic testing if medical therapy fails.

Cevap

The correct sequence is: 1) Draw a critical sample while glucose is <50< 50 mg/dL, 2) Administer glucagon to evaluate response and rescue glucose, 3) Titrate the GIR to maintain normoglycemia, 4) Initiate an oral diazoxide trial, and 5) Perform an 18F-DOPA PET scan if medical therapy fails.
The algorithm for persistent neonatal hypoglycemia is highly strict. A critical sample must be drawn first while the glucose is low to capture the inappropriate hormonal milieu. Glucagon is given immediately afterward to both confirm the diagnosis (via an exaggerated glycemic response) and protect the brain. Once the diagnosis is secured and acute rescue is provided, the continuous GIR is titrated to maintain stability. Diazoxide is then started as definitive medical therapy. If diazoxide fails over several days, surgical planning with 18F-DOPA PET and genetics is indicated.

Adım Adım Çözüm

1
Secure diagnostic evidence of hyperinsulinism.
Critical sample is drawn while glucose is <50< 50 mg/dL.
Insulin and counterregulatory hormones must be measured during active hypoglycemia to prove inappropriate secretion.
2
Perform a diagnostic and therapeutic glucagon challenge.
Glucagon is administered immediately following the critical blood draw.
Glucagon frees hepatic glycogen stores, rapidly correcting the hypoglycemia while confirming the diagnosis of hyperinsulinism (indicated by a Δ\Delta glucose >30> 30 mg/dL).
3
Establish continuous metabolic stability.
The intravenous GIR is titrated upward to 12−1512-15 mg/kg/min.
Continuous high-concentration dextrose is required to match the excessive peripheral glucose uptake driven by hyperinsulinism until long-term medications take effect.
4
Begin long-term medical management.
Oral diazoxide therapy is initiated.
Diazoxide prevents insulin release by keeping K-ATP channels open, serving as the definitive first-line medication.
5
Prepare for surgical intervention if refractory.
18F-DOPA PET imaging and genetic testing (e.g., ABCC8, KCNJ11) are ordered.
Patients failing medical therapy require pancreatectomy. PET scans accurately differentiate focal from diffuse disease to guide the surgical approach.

Anahtar Kavram

The evaluation of persistent neonatal hypoglycemia requires drawing a critical laboratory sample during active hypoglycemia (<50< 50 mg/dL), followed immediately by acute reversal (glucagon and high GIR) before initiating long-term medical (diazoxide) or surgical (guided by PET scan) interventions.
Bu soruyu puanla

Konular

Pediatric Endocrine Disorders

Bu konudan daha fazla soru